Paula Sabbo Bernardo

Paula Sabbo Bernardo

Auto-generated profile, based on publicly available information

Paula Sabbo Bernardo

Instituto Nacional de Câncer ‐ Brazilian National Cancer Institute Rio de Janeiro Brazil

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Blood Reviews
Verified
Journal Article
Closed access
PBPaula Sabbo Bernardo
Paula Sabbo Bernardo
LLLauana Greicy Tonon Lemos
Lauana Greicy Tonon Lemos
GMGabriela Nestal de Moraes
Gabriela Nestal de Moraes
RMRaquel C. Maia
Raquel C. Maia

19 August 2015 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
PSPaloma Silva de Souza
Paloma Silva de Souza
RFRoberta Soares Faccion
Roberta Soares Faccion
PBPaula Sabbo Bernardo
Paula Sabbo Bernardo
RMRaquel C. Maia
Raquel C. Maia

26 January 2018 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
RFRoberta Soares Faccion
Roberta Soares Faccion
PBPaula Sabbo Bernardo
Paula Sabbo Bernardo
GLGiselle Pinto Faria de Lopes
Giselle Pinto Faria de Lopes
LBLeonardo Soares Bastos
Leonardo Soares Bastos
CTCristina Lordello Teixeira
Cristina Lordello Teixeira
RMRaquel C. Maia
Raquel C. Maia

1 October 2008 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
FPF. M. Pereira
F. M. Pereira
PBP. S. Bernardo
P. S. Bernardo
PJP. F. F. Dias Junior
P. F. F. Dias Junior
BSB. A. Silva
B. A. Silva
MRM. T. V. Romanos
M. T. V. Romanos
André Luis SantosAndré Luis Santos
André Luis Santos

1 December 2012 in Leukemia Research
Verified
Journal Article
Closed access
PBPaula Sabbo Bernardo
Paula Sabbo Bernardo
FRFlaviana Ruade de Souza Reis
Flaviana Ruade de Souza Reis
RMRaquel C. Maia
Raquel C. Maia

1 March 2015 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
FFFernanda Costas C. de Faria
Fernanda Costas C. de Faria
MLMaria Eduarda Bento Leal
Maria Eduarda Bento Leal
PBPaula Sabbo Bernardo
Paula Sabbo Bernardo
PCPaulo R.R. Costa
Paulo R.R. Costa
RMRaquel C. Maia
Raquel C. Maia
Chronic myeloid leukemia (CML), a myeloproliferative disorder characterized by the BCR-ABL oncoprotein, presents its treatment based on tyrosine kinase inhibitors (TKIs), mainly imatinib. However, despite its clinical success, almost 30% of all CML patients demand alternative therapy. In this context, the development of drugs capable of overcoming TKIs resistance is imperative. The pterocarpanquinone-LQB-118 is a novel compound with anti-tumor effect in CML cells whose mechanism of action is being elucidated. Here, we demonstrate that in two CML cell lines exhibiting different biological characteristics, LQB-118 modulates NFκB subcellular localization, apparently independently of the AKT and MAPK pathways, partially inhibits proteasome activity, and alters the expression of microRNAs -9 and -21.